Today’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Corcept Therapeutics

U.S. markets fell sharply Tuesday for the second consecutive day. Both the Dow Jones and S&P 500 experienced their largest one day drop of 2018. The Dow Jones Industrial Average dropped 1.37 percent to close at 26,076.89, while the S&P 500 Index fell 1.09 percent to close at 2,822.43. The Nasdaq Composite Index declined 0.86 percent to close at 7,402.48. Investors appear to be awaiting details from the State of the Union address by President Donald Trump on Tuesday night.

"We’ve had a unilateral move higher [in stocks] to start things off and people are realizing this is not sustainable," said Art Hogan, chief market strategist at B. Riley FBR. "You’re also seeing some cracks in the global story with interest rates rising."

RDI Initiates Coverage on:

Bellicum Pharmaceuticals, Inc.

Corcept Therapeutics Inc.

Bellicum Pharmaceuticals stock moved 5.53% lower Tuesday, to close the day at $8.20. The company’s Cancer drug trial has been put on clinical hold due to brain damage in 3 cases.  The stock recorded a trading volume of 786,718 shares, which was above its three months average volume of 472,059 shares. In the last year, Bellicum Pharmaceuticals shares have traded in a range of 7.41 – 15.55. The stock is currently trading 47.27% below its 52 week high. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $8.66 is below its 200-day moving average of $9.87. Shares of Bellicum Pharmaceuticals have fallen roughly 2.5 percent in the past month.

Access RDI’s Bellicum Pharmaceuticals, Inc. Research Report at:

On Tuesday, shares of Corcept Therapeutics recorded a trading volume of 2,572,436 shares, which was above the three months average volume of 1,881,779 shares. The stock ended the day 7.14% lower at 23.68. The share price has gained 253.43% from its 52 week low with a 52 week trading range of 6.70 – 25.96. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $19.96 is greater than its 200-day moving average of $17.52. Shares of Corcept Therapeutics are trading at a trailing Price to Earnings ratio of 81.66. Shares of Corcept Therapeutics have gained roughly 31.12 percent in the past month.

Access RDI’s Corcept Therapeutics Inc. Research Report at:

Our Actionable Research on Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) and Corcept Therapeutics Inc. (NASDAQ:CORT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.